Inhibitory effects of SEL201 in acute myeloid leukemia

Ewa M. Kosciuczuk; Aroop K. Kar; Gavin T. Blyth; Mariafausta Fischietti; Sameem Abedin; Alain A. Mina; Rebekah Siliezar; Tomasz Rzymski; Krzysztof Brzozka; Elizabeth A. Eklund; Elspeth M. Beauchamp; Frank Eckerdt; Diana Saleiro; Leonidas C. Platanias

doi:10.18632/oncotarget.27388

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Inhibitory effects of SEL201 in acute myeloid leukemia

Ewa M. Kosciuczuk, Aroop K. Kar, Gavin T. Blyth, Mariafausta Fischietti, Sameem Abedin, Alain A. Mina, Rebekah Siliezar, Tomasz Rzymski, Krzysztof Brzozka, Elizabeth A. Eklund, Elspeth M. Beauchamp, Frank Eckerdt, Diana Saleiro and Leonidas C. Platanias _

PDF | Full Text | How to cite

Oncotarget. 2019; 10:7112-7121. https://doi.org/10.18632/oncotarget.27388

Metrics: PDF 1166 views | Full Text 2447 views | ?

Abstract

Ewa M. Kosciuczuk1^,2^,3^,*, Aroop K. Kar1^,4^,*, Gavin T. Blyth1^,2, Mariafausta Fischietti1^,2, Sameem Abedin1^,2^,5, Alain A. Mina1^,2, Rebekah Siliezar1, Tomasz Rzymski6, Krzysztof Brzozka6, Elizabeth A. Eklund1^,2^,3, Elspeth M. Beauchamp1^,2^,3, Frank Eckerdt1^,7, Diana Saleiro1^,2 and Leonidas C. Platanias1^,2^,3

1 Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA

2 Division of Hematology-Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

3 Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois, USA

4 Division of Hematology/Oncology/Stem Cell Transplantation, Department of Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA

5 Division of Hematology and Oncology Department of Medicine Medical College of Wisconsin, Milwaukee, Wisconsin, USA

6 Ryvu Therapeutics, Kraków, Poland

7 Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

* These authors contributed equally to this work

Correspondence to:

Leonidas C. Platanias,

email:

[email protected]

Keywords: acute myeloid leukemia; MNK; eIF4E; kinase inhibitor; SEL201

Received: October 17, 2019 Accepted: December 02, 2019 Published: December 24, 2019

ABSTRACT

MAPK interacting kinase (MNK), a downstream effector of mitogen-activated protein kinase (MAPK) pathways, activates eukaryotic translation initiation factor 4E (eIF4E) and plays a key role in the mRNA translation of mitogenic and antiapoptotic genes in acute myeloid leukemia (AML) cells. We examined the antileukemic properties of a novel MNK inhibitor, SEL201. Our studies provide evidence that SEL201 suppresses eIF4E phosphorylation on Ser209 in AML cell lines and in primary patient-derived AML cells. Such effects lead to growth inhibitory effects and leukemic cell apoptosis, as well as suppression of leukemic progenitor colony formation. Combination of SEL201 with 5’-azacytidine or rapamycin results in synergistic inhibition of AML cell growth. Collectively, these results suggest that SEL201 has significant antileukemic activity and further underscore the relevance of the MNK pathway in leukemogenesis.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27388

Publication Alerts

Research Papers:

Inhibitory effects of SEL201 in acute myeloid leukemia

Abstract